Literature DB >> 29414264

Risk Stratification for Sudden Cardiac Death After Myocardial Infarction.

Jonathan W Waks1,2, Alfred E Buxton1,2.   

Abstract

Sudden cardiac death (SCD) accounts for ∼50% of mortality after myocardial infarction (MI). Most SCDs result from ventricular tachyarrhythmias, and the tachycardias that precipitate cardiac arrest result from multiple mechanisms. As a result, it is highly unlikely that any single test will identify all patients at risk for SCD. Current guidelines for use of implantable cardioverter-defibrillators (ICDs) to prevent SCD are based primarily on measurement of left ventricular ejection fraction (LVEF). Although reduced LVEF is associated with increased total cardiac mortality after MI, the focus of current guidelines on LVEF omits ∼50% of patients who die suddenly. In addition, there is no evidence of a mechanistic link between reduced LVEF and arrhythmias. Thus, LVEF is neither sensitive nor specific as a tool for post-MI risk stratification. Newer tests to screen for predisposition to ventricular arrhythmias and SCD examine abnormalities of ventricular repolarization, autonomic nervous system function, and electrical heterogeneity. These tests, as well as older methods such as programmed stimulation, the signal-averaged electrocardiogram, and spontaneous ventricular ectopy, do not perform well in patients with LVEF ≤30%. Recent observational studies suggest, however, that these tests may have greater utility in patients with LVEF >30%. Because SCD results from multiple mechanisms, it is likely that combinations of risk factors will prove more precise for risk stratification. Prospective trials that evaluate the performance of risk stratification schema to determine ICD use are necessary for cost-effective reduction of the incidence of SCD after MI.

Entities:  

Keywords:  implantable cardioverter-defibrillator; myocardial infarction; risk stratification; sudden death

Mesh:

Year:  2018        PMID: 29414264     DOI: 10.1146/annurev-med-041316-090046

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  8 in total

1.  Joint Shock/Death Risk Prediction Model for Patients Considering Implantable Cardioverter-Defibrillators.

Authors:  Harrison T Reeder; Changyu Shen; Alfred E Buxton; Sebastien J Haneuse; Daniel B Kramer
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-08-15

2.  C-reactive protein: a prognostic indicator for sudden cardiac death post-myocardial infarction.

Authors:  Jordan Faulkner; Francis A Kalu
Journal:  Br J Cardiol       Date:  2020-12-02

3.  Machine Learned Cellular Phenotypes in Cardiomyopathy Predict Sudden Death.

Authors:  Albert J Rogers; Anojan Selvalingam; Mahmood I Alhusseini; David E Krummen; Cesare Corrado; Firas Abuzaid; Tina Baykaner; Christian Meyer; Paul Clopton; Wayne Giles; Peter Bailis; Steven Niederer; Paul J Wang; Wouter-Jan Rappel; Matei Zaharia; Sanjiv M Narayan
Journal:  Circ Res       Date:  2020-11-10       Impact factor: 17.367

4.  Acupuncture at Neiguan suppresses PVCs occurring post-myocardial infarction by alleviating inflammation and fibrosis.

Authors:  Hao Hong; Xin Cao; Tian Deng; Xiang-Min Meng; Yu-Meng Li; Li-Juan Zhu; Jing Lv; Xuan Li; Shu-Guang Yu; Bing-Mei Zhu
Journal:  Chin Med       Date:  2022-04-28       Impact factor: 4.546

5.  The Effects of Hypoxic Preconditioned Murine Mesenchymal Stem Cells on Post-Infarct Arrhythmias in the Mouse Model.

Authors:  Beschan Ahmad; Anna Skorska; Markus Wolfien; Haval Sadraddin; Heiko Lemcke; Praveen Vasudevan; Olaf Wolkenhauer; Gustav Steinhoff; Robert David; Ralf Gaebel
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

Review 6.  Sympathetic Activation and Arrhythmogenesis after Myocardial Infarction: Where Do We Stand?

Authors:  Konstantinos C Zekios; Eleni-Taxiarchia Mouchtouri; Panagiotis Lekkas; Dimitrios N Nikas; Theofilos M Kolettis
Journal:  J Cardiovasc Dev Dis       Date:  2021-05-15

7.  Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: As-treated and per-protocol analyses.

Authors:  Jeffrey E Olgin; Byron K Lee; Eric Vittinghoff; Daniel P Morin; Steven Zweibel; Eric Rashba; Eugene H Chung; Martin Borggrefe; Stephen Hulley; Feng Lin; Trisha F Hue; Mark J Pletcher
Journal:  J Cardiovasc Electrophysiol       Date:  2020-03-03       Impact factor: 2.942

8.  Prognostic Value of MicroRNAs in Patients after Myocardial Infarction: A Substudy of PRAGUE-18.

Authors:  M Hromádka; V Černá; M Pešta; A Kučerová; J Jarkovský; D Rajdl; R Rokyta; Z Moťovská
Journal:  Dis Markers       Date:  2019-11-03       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.